Stedical Scientific, a Hangzhou-based tissue engineering and regenerative medicine company, has raised over RMB100 million (USD13.7 million) in a Series B financing round co-led by Lapam Capital and Shanghai Healthcare Capital. The funds will support the commercial expansion of its core products, particularly in the US and China, as well as the development and clinical trials of new products.
Company Profile
Founded in 2019 and operating in both the US and China, Stedical specializes in biosynthetic membrane repair materials. Its core product is the first and only home-grown repair solution for acute and chronic wounds, with marketing approval and medical insurance coverage in the United States.
Funding Use
Proceeds from the Series B round will accelerate Stedical’s global commercialization efforts and enhance its research and development pipeline. The company holds global intellectual property rights for its technology platform, positioning it as a leader in the regenerative medicine space.-Fineline Info & Tech
